Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 5:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 210 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Pharmacogenetics Clear all
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Systemic Immunomodulatory Effects and Pharmacogenetics of Atorvastatin in Early Atherosclerosis

NCT00361283
View directory record Official record
Conditions
Inflammation
Interventions
Atorvastatin
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2009
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated May 15, 2012 · Synced Oct 22, 2026, 5:08 AM EDT
Completed Not applicable Interventional Results available

Pharmacogenetic-guided Choice of Post-surgery Analgesics

NCT05548660
View directory record Official record
Conditions
Acute Pain, Post Operative Pain
Interventions
Pharmacogenetic testing, Pharmacist note with genotype-guided analgesic recommendations, Pharmacist detailed note with genotype-guided recommendations per CPIC guidelines
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older · Female only
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Oct 22, 2026, 5:08 AM EDT
Completed Phase 3 Interventional Results available

Pharmacogenetic Treatment With Anti-Glutaminergic Agents for Comorbid PTSD & AUD

NCT02884908
View directory record Official record
Conditions
PTSD, Alcohol Use Disorder
Interventions
Pregabalin plus BBCET, Placebo plus BBCET
Drug · Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 65 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 13, 2024 · Synced Oct 22, 2026, 5:08 AM EDT
Completed Not applicable Interventional Results available

A Depression and Opioid Pragmatic Trial in Pharmacogenetics (Chronic Pain Trial)

NCT05966142
View directory record Official record
Conditions
Chronic Pain
Interventions
Pharmacogenetic testing, Clinical decisions support
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
1,048 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
10
States / cities
Gainesville, Florida • Jacksonville, Florida • Indianapolis, Indiana + 3 more
Source: ClinicalTrials.gov public record
Updated May 28, 2025 · Synced Oct 22, 2026, 5:08 AM EDT
Terminated Not applicable Interventional Results available

The Effects of Different Long-acting Bronchodilator Medications on Asthma Patients With Different Genetic Variations

NCT00706446
View directory record Official record
Conditions
Asthma
Interventions
tiotropium bromide, Salmeterol, Formoterol, Fluticasone propionate, budesonide
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 31, 2017 · Synced Oct 22, 2026, 5:08 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Obesity and Asthma: Nutrigenetic Response to Omega-3 Fatty Acids

NCT01027143
View directory record Official record
Conditions
Asthma, Obesity
Interventions
omega-3 polyunsaturated fatty acids, Omega-3 Fatty Acid
Dietary Supplement · Drug
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
12 Years to 25 Years
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
3
States / cities
Jacksonville, Florida • Orlando, Florida • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 8, 2023 · Synced Oct 22, 2026, 5:08 AM EDT
Completed Not applicable Interventional Results available

How Different Beta-2 Receptor Genotypes Affect an Asthmatic's Response to Regular Salmeterol Treatment

NCT00595361
View directory record Official record
Conditions
Asthma
Interventions
salmeterol
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 50 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
2
States / cities
Boston, Massachusetts • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 8, 2017 · Synced Oct 22, 2026, 5:08 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effects of CYP2B6 Genetic Polymorphisms on Efavirenz Pharmacokinetics

NCT00668395
View directory record Official record
Conditions
HIV
Interventions
Efavirenz
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 49 Years
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
2
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 26, 2014 · Synced Oct 22, 2026, 5:08 AM EDT
Completed Not applicable Interventional Results available

Individualized Response to Vitamin D Treatment Study

NCT02925195
View directory record Official record
Conditions
Characteristics That Modify the Response to Cholecalciferol Treatment
Interventions
Vitamin D3, Placebo
Dietary Supplement · Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
666 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
5
States / cities
Los Angeles, California • Evanston, Illinois • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2023 · Synced Oct 22, 2026, 5:08 AM EDT
Not listed No phase listed Observational

Pharmacist-led Pharmacogenomic Clinical Service Within the Program of All-inclusive Care for the Elderly

NCT04971902
View directory record Official record
Conditions
Pharmacogenetic Testing, Elderly, Opioid Use, Pain, Pain, Acute, Pain, Chronic
Interventions
Pharmacogenetic Test
Other
Lead sponsor
Tabula Rasa HealthCare
Industry
Eligibility
55 Years and older
Enrollment
2,500 participants
Timeline
2021 – 2024
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Sep 2, 2022 · Synced Oct 22, 2026, 5:08 AM EDT
Terminated Not applicable Interventional Results available

Use of Pharmacogenetics to Select Erbitux or Cisplatin to Treat Head and Neck Cancer

NCT01790516
View directory record Official record
Conditions
Head and Neck Squamous Cell Cancer
Interventions
Cisplatin, cetuximab, Radiation
Drug · Radiation
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Oct 2, 2014 · Synced Oct 22, 2026, 5:08 AM EDT
Completed No phase listed Observational

Pharmacogenomics of Mood Stabilizer Response in Bipolar Disorder (PGBD)

NCT01272531
View directory record Official record
Conditions
Bipolar Affective Disorder
Interventions
Mood stabilizer treatment
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
560 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
8
States / cities
San Diego, California • Chicago, Illinois • Indianapolis, Indiana + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2020 · Synced Oct 22, 2026, 5:08 AM EDT
Completed No phase listed Observational

MOM NEST Study: Maternal Opioid Medication: Naltrexone Efficacy Study

NCT03718104
View directory record Official record
Conditions
Opioid-use Disorder, Neonatal Abstinence Syndrome, Pregnancy, High Risk, Alcohol Use Disorder
Interventions
Pharmacokinetic analysis, Safety and Efficacy, Genetic and epigenetic analysis, Breast milk analysis
Other · Genetic
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
2
States / cities
Boston, Massachusetts • Carrboro, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 4, 2024 · Synced Oct 22, 2026, 5:08 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Pharmacogenetic Trial of Doxazosin for Treatment of Cocaine Abuse

NCT01953432
View directory record Official record
Conditions
Cocaine Dependence
Interventions
Doxazosin, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 64 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 20, 2020 · Synced Oct 22, 2026, 5:08 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Pharmacogenetics of Response to GLP1R Agonists

NCT05071898
View directory record Official record
Conditions
Obesity, Diabetes Type 2
Interventions
Semaglutide Pen Injector [Ozempic]
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 89 Years
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2028
U.S. locations
1
States / cities
Lancaster, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 22, 2026, 5:08 AM EDT
Withdrawn Phase 4 Interventional

PRospective Evaluation Comparing Initiation of Warfarin StrategiEs (PRECISE): Pharmacogenetic-guided Versus Usual Care

NCT00377143
View directory record Official record
Conditions
Blood Coagulation Disorders
Interventions
Warfarin Dosing
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 16, 2012 · Synced Oct 22, 2026, 5:08 AM EDT
Completed Phase 4 Interventional Results available

Pharmacogenomic Evaluation of Antihypertensive Responses 2

NCT01203852
View directory record Official record
Conditions
Hypertension
Interventions
Metoprolol, Chlorthalidone
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 65 Years
Enrollment
839 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
3
States / cities
Gainesville, Florida • Atlanta, Georgia • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 6, 2018 · Synced Oct 22, 2026, 5:08 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Vitamin K Supplementation Study in Healthy Volunteers (Aim 2B)

NCT04450212
View directory record Official record
Conditions
Vitamin K Status
Interventions
Phase I, Buccal Swab Collection for DNA Isolation, Phase II, Vitamin K (Vitacost) Supplementation
Genetic · Dietary Supplement
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2023
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 19, 2023 · Synced Oct 22, 2026, 5:08 AM EDT
Completed Not applicable Interventional

Prospective Pharmacogenetic Testing and Clinical Outcomes in Patients With Early-Phase Psychosis

NCT02566057
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Psychotic Disorders, Bipolar Disorder
Interventions
PGx testing guided treatment (PGT)
Biological
Lead sponsor
Northwell Health
Other
Eligibility
15 Years to 64 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Glen Oaks, New York
Source: ClinicalTrials.gov public record
Updated Jan 24, 2018 · Synced Oct 22, 2026, 5:08 AM EDT
Completed No phase listed Observational

Tamoxifen Pharmacogenetics and Clinical Effects

NCT00228930
View directory record Official record
Conditions
Breast Cancer
Interventions
Tamoxifen (pharmacodynamic analysis)
Drug
Lead sponsor
National Institute of General Medical Sciences (NIGMS)
NIH
Eligibility
18 Years to 70 Years · Female only
Enrollment
297 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
2
States / cities
Indianapolis, Indiana • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 25, 2008 · Synced Oct 22, 2026, 5:08 AM EDT
Completed Phase 2 Interventional Results available

Pharmacogenetic Testing of Saliva Samples From Patients With Five or More Exposure Days to rFVIIa Analogue in the Adept™2 Trial

NCT02541942
View directory record Official record
Conditions
Congenital Bleeding Disorder, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors
Interventions
No treatment given
Other
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
12 Years and older · Male only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
5
States / cities
Tucson, Arizona • Tampa, Florida • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2019 · Synced Oct 22, 2026, 5:08 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Disulfiram for Cocaine Abuse

NCT00395850
View directory record Official record
Conditions
Cocaine Dependence
Interventions
Disulfiram
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 65 Years
Enrollment
118 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Nov 13, 2013 · Synced Oct 22, 2026, 5:08 AM EDT
Completed Phase 1Phase 2 Interventional

Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer, Ovarian Cancer, or Squamous Cell Carcinoma of the Head and Neck

NCT00063895
View directory record Official record
Conditions
Recurrent Non-small Cell Lung Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Nasopharynx, Recurrent Squamous Cell Carcinoma of the Oropharynx, Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx, Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage III Squamous Cell Carcinoma of the Nasopharynx, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage IIIA Non-small Cell Lung Cancer, Stage IIIA Ovarian Epithelial Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IIIB Ovarian Epithelial Cancer, Stage IIIC Ovarian Epithelial Cancer, Stage IV Non-small Cell Lung Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IVA Squamous Cell Carcinoma of the Larynx, Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVA Squamous Cell Carcinoma of the Oropharynx, Stage IVB Squamous Cell Carcinoma of the Larynx, Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVB Squamous Cell Carcinoma of the Oropharynx, Stage IVC Squamous Cell Carcinoma of the Larynx, Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVC Squamous Cell Carcinoma of the Oropharynx
Interventions
erlotinib hydrochloride, pharmacological study, pharmacogenomic studies, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 9, 2013 · Synced Oct 22, 2026, 5:08 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Interventional Testing of Gene-environment Interactions Via the Verifomics Mobile Application

NCT02758990
View directory record Official record
Conditions
Obesity, Rhinitis, Rhinitis, Allergic, Respiratory Sounds, Dyspnea, Headache, Migraine Disorders, Arthritis, Arthralgia, Anxiety, Sleep Initiation and Maintenance Disorders, Sleep Deprivation
Interventions
Vitamin A, Vitamin B6, Vitamin C, Nicotinamide, Vitamin D3, Vitamin E, Broccoli, Spinach, Caffeine, Coffee, Axon Eyewear, Chocolate
Dietary Supplement · Other · Device
Lead sponsor
Verifomics LLC
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 2, 2017 · Synced Oct 22, 2026, 5:08 AM EDT